BioWorld

Feb. 21, 2002

IDEC Gains Zevalin Approval For Non-Hodgkin’s Lymphoma

IDEC Pharmaceuticals Corp. received FDA approval of Zevalin to treat non-Hodgkin’s lymphoma and is poised to introduce the first radioimmunotherapy to the United States. (BioWorld Today) Read More

Fresh From Mergers, Buyouts, CEOs Mull Boons And Pitfalls

Pseudomonas aeruginosa, Lethal Cystic Fibrosis Scourge, Trades Surprise Blows With Scientists

Avant Dropping TP10 Following Phase II Failure; Stock Tumbles

Other News To Note

Bush Might Have Final Say On Biotech’s Role In Bioterrorism

Anadys, Structural GenomiX Form Antibacterials Alliance

Today's news in brief

BioWorld

IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

BioWorld Science

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...

TL1A is overexpressed in hidradenitis suppurativa

BioWorld Science

Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...

Illustration of head with maze that is missing parts

Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke

BioWorld Science

Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...

VST Bio’s VB-001 is neuroprotector after stroke

BioWorld Science

At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...